Who: Eli Lilly

Based: United States

2006 Pipeline Budget: $3.47 billion (€2.37B)

2007 Pipeline News: Lilly's biggest hope right now is prasrugel, an anti-clotting drug designed to take on the blockbuster Plavix. In a recent trial prasugrel outperformed Plavix when it came to reducing the number of heart attacks and other significant events. However, prasrugel demonstrated an increased number of bleeding incidents [0], leading analysts to question whether the FDA will approve the drug. Other than prasrugel, analysts recently noted [0] that there are no other potential blockbusters in Lilly's pipeline. This is extremely bad news for Lilly: A series of upcoming patent expirations could potentially trim up to 60 percent of its revenue.

Pending approval:

Prasugrel - Acute coronary syndrome

Phase III:

Enzastaurin - Non-hodgkin's lymphoma
Arzoxifene - Osteoporosis & prevention of breast cancer
Inhaled insulin

Company Pipeline Site: Link [1]